AI Consensus Investment Thesis
Regeneron Pharmaceuticals (REGN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$883
+12.4%+12.9% incl. dividends5-Year
BUY$1,302
+65.9%+69.2% incl. dividendsLatest flagship insight
Unencumbered Cash Royalty Inflection Overpowers Terminal Biopharma Patent Cliff Fears
High consensus confirms that unencumbered partner royalties and high-dose formulation defense offset legacy biosimilar erosion, driving structural free cash flow expansion. While sharp divergence exists regarding outer-year terminal multiple compression ahead of 2031 patent expirations, pristine net cash provides defensive insulation.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Ray Dalio (Strategist), Universal Investor (Polymath), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Machiavelli (Insider), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower), Elon Musk (Visionary), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Regeneron Pharmaceuticals at the forecast anchor (2026-09-18): $16,920 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 0.4% net dividend yield for Regeneron Pharmaceuticals.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 815.86 | +3.95% | +3.95% | Reported results confirm the initial profit uplift following full satisfaction of partner development liabilities. Expanding immunology royalties and steady high-dose ocular conversion absorb broader equity market rate volatility, driving moderate valuation stabilization. |
| Q1 2027 | 819.38 | +0.43% | +4.40% | Initial standard-dose biosimilar entries introduce wholesale pricing concessions, producing tactical margin friction. However, high-dose volume retention and uninterrupted partner cash flows limit downside, maintaining orderly per-share fundamental consolidation. |
| Q2 2027 | 853.60 | +4.18% | +8.76% | Unencumbered collaboration cash flows expand reported operating margins by several hundred basis points. Sustained global respiratory volume growth accelerates cash generation, driving consensus upward revisions across institutional equity research desks. |
| Q3 2027 | 882.56 | +3.39% | +12.45% | High-dose formulation captures over sixty percent of franchise volume, blunting competitive generic headlines. Accelerated share repurchases funded by substantial liquid reserves steadily absorb floating equity supply, bolstering per-share intrinsic value. |
| Q4 2027 | 914.14 | +3.58% | +16.47% | Late-stage pipeline progression across oncology and metabolic indications improves terminal visibility. Year-end portfolio rebalancing favors cash-generative biopharmaceutical assets with zero net leverage, supporting steady multiple resilience against macro rate persistence. |
| Q1 2028 | 924.80 | +1.17% | +17.83% | Annual financial reporting showcases record operational cash flow exceeding four billion dollars. Statutory federal pricing disclosures create transient headline drag, but superior balance-sheet strength and ex-U.S. expansion cushion operating profitability. |
| Q2 2028 | 960.98 | +3.91% | +22.44% | Pivotal clinical trial readouts for adjunctive metabolic therapies demonstrate functional lean-mass preservation, sparking institutional interest. Concurrently, unencumbered partnership income reaches new records, sustaining robust top-line momentum across core disease areas. |
| Q3 2028 | 990.47 | +3.07% | +26.20% | Commercial execution proves high-dose retinal regimens effectively lock in specialist loyalty despite multi-competitor generic availability. Systematic treasury buybacks continue shrinking diluted share count, compounding fundamental earnings per share growth. |
| Q4 2028 | 1,026.10 | +3.60% | +30.74% | Global immunology sales maintain strong double-digit expansion, dropping significant cash directly to the bottom line. Corporate leadership expands capital return authorizations, closing the year with solid operational performance and pristine liquidity. |
| Q1 2029 | 1,053.77 | +2.70% | +34.26% | Full-year results confirm operating margins stabilizing near peak levels. However, analysts begin publishing long-term exclusivity transition scenarios, causing modest multiple restraint even as underlying business net earnings advance. |
| Q2 2029 | 1,079.91 | +2.48% | +37.59% | Initial two-year forward discounting of key biologic patent expiries introduces valuation friction. Pipeline diversification into bispecific oncology and rare diseases accelerates, partially counterbalancing market-wide duration trimming among institutional investors. |
| Q3 2029 | 1,108.81 | +2.68% | +41.28% | Accretive share repurchases executed at discounted forward multiples mechanically support equity value. Commercial revenues from wholly owned oncology products expand, proving internal research efficiency replaces aging revenue pillars without dilutive acquisitions. |
| Q4 2029 | 1,138.92 | +2.72% | +45.11% | Expanded international penetration across emerging territories offsets domestic reimbursement concessions. High cash conversion sustains significant internal laboratory reinvestment while preserving an unassailable net-cash fortress against broader macroeconomic instability. |
| Q1 2030 | 1,153.66 | +1.29% | +46.99% | Full-year filings show cumulative five-year share shrinkage approaching fifteen percent, magnifying per-share metrics. Nevertheless, closer proximity to prime compound patent dates caps price-to-earnings expansion, keeping capital appreciation disciplined. |
| Q2 2030 | 1,186.35 | +2.83% | +51.16% | Commercial rollout of adjacent metabolic therapies and next-generation bispecifics begins generating meaningful revenue streams. Operational scale and high gross margins ensure cash flow remains resilient through shifting competitive dynamics. |
| Q3 2030 | 1,201.12 | +1.25% | +53.04% | Generalist institutional capital selectively de-risks ahead of terminal patent milestones, inducing modest multiple compression. Defensive pharmaceutical demand and zero refinancing vulnerability limit downside volatility relative to broader healthcare equities. |
| Q4 2030 | 1,233.15 | +2.67% | +57.12% | Final pre-cliff financial disclosures deliver record free cash flow, attracting value-focused institutional buyers. Treasury execution aggressively retires shares, establishing firm valuation support and closing the year on sound operational delivery. |
| Q1 2031 | 1,244.03 | +0.88% | +58.51% | Primary composition-of-matter exclusivity expiration generates elevated media scrutiny and short-term multiple de-rating. Underlying operations remain robust as secondary formulation protections, complex manufacturing, and patient stickiness prevent immediate revenue collapse. |
| Q2 2031 | 1,276.23 | +2.59% | +62.61% | Observed commercial erosion proves substantially more gradual than pessimistic models projected, supported by durable international contracts and device patents. A relief repricing unfolds as first-half cash realization exceeds cautious trough expectations. |
| Q3 2031 | 1,301.75 | +2.00% | +65.86% | The five-year transformation culminates with an unencumbered, multi-pillar commercial structure. Substantially reduced share count, newly scaled oncology and metabolic franchises, and pristine liquidity establish an enduring, high-return biopharmaceutical compounder. |
The central economic argument resolves the conflict between imminent patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry and structural cash-flow acceleration. While legacy standard-dose aflibercept faces multi-competitor biosimilar erosion, rapid commercial migration to the high-dose formulation effectively insulates retinal cash flows through extended dosing durability. Concurrently, the mid-2026 satisfaction of the partner development balance permanently eliminates historical collaboration profit withholdings, releasing an unencumbered cash waterfall from expanding global immunology indications. Trading near nineteen times trailing earnings, the asset heavily discounts this margin step-up. Valuation sensitivity centers on terminal multipleterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry compression: as the March 2031 compound patent expiration approaches, multiple contraction will partially offset substantial non-GAAP earnings compounding. The primary counterargument warns that aggressive payer step-therapy mandates could accelerate retinal pricing deflation while heavy expensed research outlays drag intermediate operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry.
Key insights
- Unencumbered collaboration profit splits structurally elevate operating cash generation, converting expanding global respiratory volumes into high-margin net income without incremental capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry.
- High-dose formulation switching dynamics create steep physician switching barriers, neutralizing first-wave generic biosimilar encroachment and extending ophthalmic cash-flow duration.
- Pristine net liquidity exceeding fifteen billion dollars facilitates continuous anti-dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry cannibalization, mechanically amplifying per-share intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry through cyclical macroeconomic fluctuations.
Many investors worry that expiring patents on older eye medicines will crush profits. However, the business is executing a successful two-part turnaround. First, patients are rapidly switching to an improved, longer-lasting eye treatment that generic copies cannot easily replace. Second, the company completely paid off a multi-billion-dollar partnership debt, allowing it to keep far more profit from its blockbuster immunology drug as global sales soar. Supported by billions in cash reserves and zero net debtnet debtTotal debt minus cash and cash equivalents.View full glossary entry, the company is using surplus cash to buy back its own stock, compounding per-share value.
Key insights
- Fully paying off partnership development obligations lets significantly more high-margin cash flow directly into company earnings.
- Upgraded high-dose formulations keep eye doctors and patients loyal, blunting cheap generic competition.
- A debt-free balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry and steady buybacks reliably protect and grow shareholder value per share.
Deep Dive
Prevailing market sentiment treats the business as an ex-growth asset trapped behind an insurmountable patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry. Consensus fixates on incoming aflibercept biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and legislative drug price negotiations, assuming eye-care revenue will collapse. Sell-side models anchor heavily on legacy product margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry, lazily projecting terminal decay while overlooking the cash inflection created by the extinguished partnership development debt and accelerating respiratory therapy expansion.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market sentiment treats the business as an ex-growth asset trapped behind an insurmountable patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry. Consensus fixates on incoming aflibercept biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and legislative drug price negotiations, assuming eye-care revenue will collapse. Sell-side models anchor heavily on legacy product margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry, lazily projecting terminal decay while overlooking the cash inflection created by the extinguished partnership development debt and accelerating respiratory therapy expansion.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value by mistaking a managed lifecycle transition for structural obsolescence. Market participants commit an analytical error by valuing the equity against historical financials that included substantial partner development withholdings, which fully terminated in mid-2026. Furthermore, consensus fails to recognize that high-dose conversions preserve specialized eye revenues, while nearly six billion dollars in expensed annual scientific discovery conceals true economic earning power. This creates a compelling underpricing gap relative to durable recurring cash flows.
Repricing Catalyst
What could make the market recognize and close that gap? Consecutive quarterly financial reports through 2027 will expose the market's mispricing as unencumbered partnership profits visibly expand reported operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry. Tangible evidence will emerge as high-dose retinal market share surpasses sixty percent while immunology revenue outpaces legacy price erosion. This operational delivery will force sell-side analysts to execute upward earnings-per-share revisions and dismantle terminal-decline valuation assumptions.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment assessments agree on pervasive market fear regarding biosimilar patent cliffs but diverge sharply on outer-year volatility. Disagreement centers on whether impending 2031 exclusivity expirations will induce multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry or permit sustained multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry driven by metabolic pipeline breakthroughs.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing restrictive monetary policy regime of four percent benchmark interest rates acts as a relative tailwind for this asset. Operating with negative net debtnet debtTotal debt minus cash and cash equivalents.View full glossary entry and over fifteen billion dollars in liquid reserves, the company generates significant interest income while leveraged biotech competitors suffer. Inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry for sight-saving and chronic inflammatory treatments provides robust pricing insulation against broader macroeconomic volatility.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive debate centers on valuation horizon and terminal exclusivity dynamics rather than near-term operational health. Bullish reports model sustained multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry past twenty-two times forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry, assuming proprietary metabolic and oncology pipelinesoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry will seamlessly offset maturing blockbusters. Conversely, more skeptical assessments point to historical precedent, arguing that large-cap biopharma multiples inevitably compress into the low-to-mid teens as primary compound patents near expiration, irrespective of pipeline potential. Resolving this conflict requires monitoring whether high-dose retinal formulations maintain volume above sixty percent against 2027 biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry and whether Phase 3 metabolic data demonstrate reimbursable functional endpoints.
Base-Case Forces
Event Risk ScoreModerate45/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Unencumbered immunology collaboration profit unlock | Operational Efficiency | +27% | +36% | Full satisfaction of the historical partner development balance in mid-2026 permanently eliminates collaboration profit withholdings. This structural reset allows the complete fifty-percent commercial profit split to drop directly to operating income. Supported by blockbuster expansion into chronic obstructive pulmonary disease, high-margin royalty streams expand significantly across the forecast horizon. |
| High-dose formulation ophthalmic franchise defense | Innovation And Product | +18% | +20% | Rapid clinical adoption of the high-dose eight-milligram formulation preserves ophthalmic franchise cash generation against incoming standard-dose biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry. Extended dosing intervals up to sixteen and twenty weeks erect formidable prescriber switching frictions. High-dose conversion protects net realized pricing, cushioning the business against legacy volume loss through dense secondary patent estates. |
| Disciplined anti-dilutive share retirement compounding | Capital Allocation | +15% | +13% | Management consistently channels substantial free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry into open-market share repurchases, retiring approximately three to four percent of outstanding equity annually. Backed by pristine net liquidity and zero debt-refinancing exposure, continuous float reductionfloat reductionA decrease in publicly tradable shares, often caused by repurchases, acquisitions, or insider ownership changes.View full glossary entry mechanically accelerates per-share earnings growth, establishing a durable fundamental floor beneath quoted equity valuations. |
| Proprietary genetic platform discovery productivity | Operational Efficiency | +16% | +17% | The integrated genetic discovery engine and antibody validation technologies consistently deliver proprietary clinical candidates at a fraction of external licensing costs. Generating validated oncology bispecifics and rare disease assets in-house preserves high returns on capital, systematically replacing maturing commercial therapies with wholly owned, patent-protected biological monopolies. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Standard-dose aflibercept biosimilar pricing compression | Competitive Positioning | -18% | -21% | Multiple settled biosimilar entries beginning late 2026 force steep price discounting on legacy two-milligram vials. Payer step-edits and commercial formulary tiering mandate cheaper alternatives, eroding baseline ophthalmic net realization. While high-dose migration mitigates volume loss, the aggregate retinal revenue pool faces inevitable margin drag over the medium term. |
| March 2031 compound patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry discounting | Regulatory | -15% | -5.0% | The primary United States composition-of-matter patent for the flagship immunology biologic expires in March 2031. Because institutional equity markets discount biologic loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry two to three years in advance, valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression will increasingly penalize forward earningsforward earningsEstimated future profitability used to calculate valuation multiples for investment analysis.View full glossary entry from 2029 onward despite expanding underlying operational revenue. |
| High expensed scientific research intensity | Capital Allocation | -10% | -13% | Management maintains an aggressive discovery commitment, pouring nearly six billion dollars annually into internal research and development at over thirty-five percent of revenues. Fully expensing late-stage clinical programs directly against current income depresses reported accounting margins, constraining near-term operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry during macroeconomic tightening cycles. |
| Federal drug price negotiation frameworks | Regulatory | -10% | -12% | Statutory drug price negotiation mandates under federal healthcare legislation enforce mandatory ceiling discounts and rebate penalties on mature biologic blockbusters. Increasing public-payer scrutiny across Medicare Part B and Part D channels threatens net realized pricing, dampening the long-term earnings potential of high-expenditure chronic commercial therapies. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Judicial invalidation of high-dose formulation patents | 27% | -28% | An unexpected federal appellate ruling overturning preliminary injunctions and invalidating secondary patents protecting high-dose aflibercept would allow immediate generic eight-milligram market entry. Dismantling the retinal lifecycle defense would trigger violent thirty-to-fifty percent price deflation, slashing domestic ophthalmology cash generation by over a billion dollars annually. |
| Binary Phase 3 pipeline failure shock | 23% | -24% | Severe safety alerts or statistical failure in pivotal late-stage cardiometabolic or bispecific oncology trials would eliminate critical pipeline diversification options. Mirroring past single-day trial setbacks, stranded developmental capital and the loss of post-2031 replacement revenue would trigger an abrupt de-rating toward low-teens terminal multiplesterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Cardiometabolic obesity muscle preservation breakthrough | 34% | +36% | Pivotal Phase 3 clinical data validating trevogrumab in combination with incretin agonists could establish a dominant therapeutic standard for preserving lean muscle mass during weight loss. Proving functional body composition benefits would unlock a massive multi-billion-dollar adjunctive metabolic market by 2028, sparking aggressive multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| Immunology primary patent exclusivity extension | 32% | +25% | Favorable patent term extensions and federal court validation of secondary formulation and method-of-treatment claims could stretch core immunology exclusivity past 2033. Disclosed legal victories would eliminate the looming terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry overhang, prompting immediate double-digit structural repricingstructural repricingA lasting change in market price or valuation caused by a reassessment of long-term fundamentals or risk.View full glossary entry across institutional discounted cash flow models. |
Company Financial Analysis
Regeneron Pharmaceuticals Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
The company's headline financial results show an accelerating top line, with second-quarter 2026 revenue expanding 17% year-over-year to $4.29 billion. Although accounting net income dipped slightly due to clinical trial spending and one-off research charges, cash flow tells a much stronger story. Blockbuster immunology sales surged 38% globally to $6.0 billion, demonstrating that demand is expanding rather than slowing. Crucially, the full repayment of a $3.1 billion partnership development balance in mid-2026 fundamentally changes the earnings picture. Operating free cash flow of $3.52 billion easily funds heavy research reinvestment. Removing historical partnership profit deductions allows commercial gains to flow directly into company earnings, establishing a higher, unencumbered baseline for future profits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 14.3B | USD 4.5B | USD 4.1B |
| 2024 | USD 14.2B | USD 4.4B | USD 3.7B |
| 2023 | USD 13.1B | USD 4B | USD 3.7B |
| 2022 | USD 12.2B | USD 4.3B | USD 4.4B |
| 2021 | USD 16.1B | USD 8.1B | USD 6.5B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.4x | TTM | Native | USD / USD |
| 2024 | 18.4x | TTM | Native | USD / USD |
| 2023 | 25.3x | TTM | Native | USD / USD |
| 2022 | 19.0x | Annual | Native | USD / USD |
| 2021 | 8.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gross profit margins remain world-class at 85.4%, demonstrating formidable pricing power and highly efficient manufacturing across complex biologic therapies. Operating margins moderated toward 25% from pandemic peaks, driven entirely by deliberate increases in research spending and promotional costs for new product launches rather than structural operational decay. Profit margins are now positioned for a structural rebound. Eliminating the partnership development reimbursement liability removes a multi-hundred-million-dollar quarterly profit drag. As high-margin partnership royalties flow unhindered and upgraded high-dose formulations achieve manufacturing scale, operating margins should naturally expand back toward 30% over the coming years.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 3.6B | 24.9% | 31.4% |
| 2024 | USD 4B | 28.1% | 31.1% |
| 2023 | USD 4B | 30.9% | 30.1% |
| 2022 | USD 5.4B | 44.2% | 35.6% |
| 2021 | USD 8.9B | 55.7% | 50.2% |
Balance sheet and leverage
AI Review
The balance sheet functions as an impregnable financial fortress, holding over $17.8 billion in cash and marketable securities against minimal gross debt. With a debt-to-equity ratio of just 0.09 and an interest coverage ratio exceeding 120 times, the company faces virtually zero financial solvency risk in a high-interest-rate environment. This pristine liquidity structure provides total strategic autonomy. Unburdened by debt covenants or refinancing pressures, management deployed nearly $4.0 billion into share buybacks in 2025. This exceptional financial strength allows the business to fund late-stage clinical programs independently while taking advantage of market dips to retire undervalued shares.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 2.7B | USD 8.6B | USD 412.2M net cash | 4.13x |
| 2024 | USD 2.7B | USD 9B | USD 216.2M net debt | 4.73x |
| 2023 | USD 2.7B | USD 10.8B | USD 27.1M net cash | 5.69x |
| 2022 | USD 2.7B | USD 7.7B | USD 404.5M net cash | 5.06x |
| 2021 | USD 2.7B | USD 5.7B | USD 185.9M net cash | 3.56x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management's capital strategy focuses heavily on internal scientific discovery rather than buying expensive external businesses. Physical spending on buildings and manufacturing remained modest at roughly 6.3% of revenue in 2025, directed toward state-of-the-art biologic facilities. In contrast, expensed research and development absorbed $5.85 billion, representing nearly 40% of sales. This massive research commitment depresses short-term reported accounting profits, but it builds valuable long-term biological assets. By inventing medicines in-house through proprietary genetic platforms, the company avoids dilutive acquisitions and creates high returns on capital. This internal development pipeline ensures a steady stream of next-generation therapies to replace older mature products.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 898.4M | USD 5.9B |
| 2024 | USD 755.9M | USD 5.2B |
| 2023 | USD 926.4M | USD 4.4B |
| 2022 | USD 590.1M | USD 3.1B |
| 2021 | USD 551.9M | USD 2.6B |
Quarterly Forecast Scenarios
Regeneron Pharmaceuticals Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $800.55 | $814.56 | $847.64 | $750.26 | |
| $776.53 | $821.46 | $848.89 | $736.44 | |
| $815.36 | $854.83 | $882.85 | $743.40 | |
| $832.64 | $883.54 | $917.56 | $755.15 | |
| $865.95 | $914.36 | $950.80 | $776.22 | |
| $854.91 | $930.61 | $974.08 | $787.13 | |
| $897.66 | $965.08 | $1,023 | $802.83 | |
| $918.86 | $994.72 | $1,053 | $812.05 | |
| $955.62 | $1,031 | $1,095 | $839.18 | |
| $974.73 | $1,061 | $1,136 | $850.50 | |
| $951.38 | $1,091 | $1,185 | $872.39 | |
| $979.92 | $1,121 | $1,232 | $885.51 | |
| $999.52 | $1,150 | $1,269 | $909.56 | |
| $959.54 | $1,173 | $1,320 | $916.13 | |
| $978.73 | $1,208 | $1,373 | $936.51 | |
| $949.37 | $1,227 | $1,414 | $947.34 | |
| $968.36 | $1,260 | $1,442 | $969.59 | |
| $919.94 | $1,276 | $1,486 | $979.99 | |
| $947.54 | $1,309 | $1,515 | $999.60 | |
| $966.49 | $1,335 | $1,546 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus reveals an enterprise executing an effective commercial transition: full repayment of the multi-billion-dollar partner development balance in mid-2026 unlocks unencumbered immunology profit splits, while high-dose retinal adoption insulates core ophthalmic volume against standard biosimilars. However, correlated assumptions across several reports treat pipeline options as guaranteed commercial blockbusters and underestimate outer-year multiple compression ahead of the March 2031 primary compound expiration. The strongest contrarian perspective demonstrates that even with robust near-term earnings growth, valuation multiples naturally compress as terminal patent expiries enter standard institutional discounting windows. Material limitations include unresolved regulatory price-setting under federal frameworks and clinical translation uncertainty in adjacent metabolic combinations. Consequently, weight is concentrated in reports demonstrating rigorous primary-source grounding, audited collaboration mechanics, and disciplined terminal multiple restraint.
Universal Investor AI
The Polymath
Opus 5Exceptional primary-source grounding across filings, patent settlements, and clinical trial results anchors a realistic terminal discounting framework. By properly modeling the 2029-2031 multiple compression ahead of compound patent expiration, it delivers superior causal consistency.
Universal Investor AI
The Polymath
GPT-6 AstraExceptional primary financial verification accurately separates operating cash flow from non-operating distortions. Its balanced bridge models post-repayment margin uplift alongside persistent R&D intensity, providing an objective, highly disciplined valuation foundation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis analysis provides excellent empirical detail on quarterly collaboration receipts, reimbursement dynamics, and cash conversion cycles. Its conservative trajectory accounts for patent cliff headwinds while crediting unencumbered cash flows, justifying high relative conviction.
Universal Investor AI
The Polymath
Gemini 3.8 FlashStrong forensic accounting links top-line expansion to unencumbered collaboration receipts while maintaining realistic expectations for clinical pipeline progress. It provides balanced treatment of operating reinvestment, earning an above-average weight.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashComprehensive verification of patent settlement dates and high-dose conversion benchmarks provides high evidential rigor. Its realistic compounding path connects robust cash generation with continuous share buybacks, supporting a solid allocation.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashRigorous macroeconomic positioning highlights the fortress balance sheet's resilience amid restrictive interest rates. Its debt-free compounding thesis is causal and robust, though outer-year multiple expansion assumptions are moderately generous.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThe thesis provides solid mechanistic clarity regarding the Sanofi development debt payoff and high-dose formulation switching dynamics. However, its earnings trajectory slightly understates regulatory drug price negotiation friction, justifying a measured weighting.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThe perspective offers sharp tactical insight into reimbursement contracts and executive pricing strategy. While its political durability assumptions are somewhat optimistic, its evaluation of payer step-therapy risks is highly grounded and actionable.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashForensic balance sheet verification confirms the full satisfaction of off-balance-sheet collaboration liabilities. The thesis accurately isolates the operating margin inflection while maintaining prudent skepticism regarding recent oncology pipeline setbacks.
Elon Musk AI
The Visionary
Gemini 3.8 FlashInsightful appraisal of genetic discovery technology and body composition pharmacology is tempered by excessive optimism regarding early metabolic monetization. It receives a moderate weight reflecting valuable platform analysis offset by speculative execution timing.
Michael Burry AI
The Vulture
Gemini 3.8 FlashStrong focus on replacement asset value and downside margin of safety provides solid defensive grounding. However, its trajectory anticipates rapid multiple re-rating that partially conflicts with late-horizon patent cliff discounting.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis report accurately identifies the structural shift toward immunology royalties but aggressively discounts competitive biosimilar pricing friction in retinal care. While its balance sheet analysis is sound, excessive optimism on immediate multiple expansion warrants a modest allocation.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThe assessment correctly emphasizes owner earnings and capital returns through equity retirement. However, its qualitative moat defense understates the severe margin drag resulting from mandatory payer biosimilar step edits over the medium term.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashWhile franchise conversion metrics are well-documented, the projected valuation path aggressively discounts patent expiry headwinds and assumes near-flawless metabolic pipeline execution, warranting a lower weight to prevent valuation overshoot.
Research Provenance
References & Context
This Regeneron Pharmaceuticals consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 132 deduplicated sources retained for this batch.
- 01REGENERON PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
- 02REGENERON PHARMACEUTICALS, INC. - Form 8-K - FY2026sec.gov
- 03Sanofi - Form 6-K - FY2026sec.gov
- 04Regeneron stock holds below recent high as HSBC lifts targetad-hoc-news.de
- 05Formycon and Regeneron Settle European Aflibercept Biosimilar Litigation - Big Molecule Watchbigmoleculewatch.com
- 06Regeneron and Biocon Settle Litigation over EYLEA® Biosimilar Yesafili™ — Venable's BiologicsHQbiologicshq.com
- 07Mixed COPD results for Regeneron, Sanofi drug cloud approval chances | BioPharma Divebiopharmadive.com
- 08Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026fiercepharma.com
- 09With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivityfiercepharma.com
- 10[REGN] Regeneron Reports Second Quarter 2026 Financial and Operating Results — BigGo Financefinance.biggo.com
- 11ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospectsfinance.yahoo.com
- 12How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline Developmentsfinance.yahoo.com
- 13Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ...finance.yahoo.com
- 14Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strengthfinance.yahoo.com
- 15Regeneron at Morgan Stanley conference: growth leans on dupixent By Investing.comin.investing.com
And 117 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.